Edgewise Therapeutics, Inc. EWTX

EWTX Company Overview

Edgewise Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing precision medicines for severe neuromuscular and cardiac diseases. The company primarily operates within the biotechnology and rare disease therapeutics industries, with a research emphasis on genetically defined muscle disorders. Its core strategy centers on discovering and developing small-molecule therapies designed to improve muscle function by targeting key regulators of muscle contraction and stability.

The company’s primary programs have focused on disorders such as Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and hypertrophic cardiomyopathy (HCM). Its lead product candidates include compounds targeting fast skeletal muscle and cardiac muscle function through selective modulation of sarcomeric proteins. Edgewise was founded in 2017 and evolved from a discovery-stage biotechnology company into a publicly traded clinical-stage developer following its Nasdaq listing in 2021. The company has positioned itself around differentiated muscle biology expertise, proprietary drug discovery capabilities, and a focus on orally administered therapies for rare neuromuscular conditions.